Motion-model Ultrasound Localization Microscopy (mULM) for Diagnostics and Therapy Monitoring in Breast Carcinoma

Klinik für Gynäkologie und Geburtshilfe RWTH Aachen0 个研究点目标入组 74 人开始时间: 2021年1月7日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. patients with histologically confirmed primary breast carcinoma including all intrinsic subtypes (study part A and B) and patients with high-grade suspicion of primary breast carcinoma (study part C).
•2. treatment with neoadjuvant chemotherapy (study part A and B)
•3. written informed consent
•4. subjects who are legally competent and mentally able to comply with the instructions of the study personnel

•1. minority
•2. hypersensitivity / allergy to ultrasound contrast agent or its components sulfur hexafluoride, macrogol 4000, colfosceril stearate, 1-(1,2-dipalmitoyl-3-sn-phosphatidyl)glycerol sodium salt palmitic acid
•3. right-left shunt
•4. signs of cardiovascular instability
•5. acute endocarditis
•6. artificial heart valves
•7. acute systemic inflammation and/or sepsis
•8. overactive coagulation status and/or recent thromboembolism
•9. end-stage renal or hepatic disease
•10. severe pulmonary hypertension (pulmonary arterial pressure > 90 mmHG)
•11. uncontrolled systemic hypertension
•12. acute respiratory distress syndrome
•13. pregnant women
•14. persons who are institutionalized by administrative or judicial order
•15. persons who are in a dependent or employment relationship with the sponsor or investigator
•16. alcohol and drug abuse
•17. expected non-compliance

发起方

Klinik für Gynäkologie und Geburtshilfe RWTH Aachen